Interventional psychiatry as a service line

What counts as interventional

For most of its history, psychiatry delivered two things: conversation and prescriptions. Interventional psychiatry is the growing corner that delivers a procedure instead. In practice that means three things today.

Electroconvulsive therapy, which remains among the most effective treatments in the field for severe depression and catatonia and is also the most stigmatized, largely for reasons that have to do with film rather than data. Transcranial magnetic stimulation, which is noninvasive, delivered in a course of daily sessions over weeks, and now widely available. And esketamine, which is the newest and the one that most clearly reveals what "procedure" does to a practice.

The REMS reality

Esketamine, sold as Spravato, was approved by the FDA in March 2019 for treatment-resistant depression, with the indication expanded in 2020. But approval is where the story starts rather than ends, because it's available only through a restricted Risk Evaluation and Mitigation Strategy program.

What that means concretely, and clinicians new to it are consistently surprised by how much it means:

• The healthcare setting must be REMS-certified. So must the pharmacy.
• The patient must be enrolled in the program.
• The dose is self-administered but on site, under supervision. It doesn't go home with anyone.
• The patient is monitored for at least two hours after each dose, with vitals and safety checks documented.

Confirm the current requirements before you build anything around this, because REMS programs are modified over time.

Why the chair is the constraint

Now look at that two-hour monitoring window as a business, because that's what determines whether this exists in your community.

A prescription consumes fifteen minutes of a psychiatrist's time. An esketamine dose consumes a room, a monitored chair, and staff attention for over two hours, repeatedly, per patient, during the induction phase. The physician isn't the bottleneck. The chair is. TMS has the same shape: a course is many sessions, each occupying a device and a room.

That's why interventional psychiatry concentrates into dedicated clinics rather than diffusing into ordinary outpatient practice. It isn't a service you bolt onto a standard schedule. It's a different operating model, with capital, space, staffing, and reimbursement questions attached, and it's the closest psychiatry gets to running like a procedural specialty. The revenue estimator assumes a visit-based model and simply doesn't describe this.

What it means for access

Two honest consequences.

First, these treatments concentrate where the capital is. A monitored chair, a TMS device, and certified staff are not things a solo rural practice acquires casually, so interventional psychiatry deepens the geographic access gap described in where the psychiatrists are. The patients most likely to have treatment-resistant illness are not reliably the ones near a clinic that can treat it.

Second, it pulls psychiatrists toward it, because the economics can work in a way that fifteen-minute follow-ups don't. That's a rational response by individual clinicians and a distributional problem in aggregate, which is the same pattern this site keeps finding: nobody is behaving badly, and the system still produces a result nobody would design.